NCT02063958 2018-07-30Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine TumorsEsanex Inc.Phase 1 Completed19 enrolled
NCT01635712 2017-04-26Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological MalignanciesEsanex Inc.Phase 1 Completed10 enrolled
NCT01851096 2016-08-16Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung AdenocarcinomaEsanex Inc.Phase 1 Completed17 enrolled
NCT01611623 2013-04-02Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor MalignanciesEsanex Inc.Phase 1 Completed9 enrolled
NCT00506805 2012-05-28Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor MalignanciesEsanex Inc.Phase 1 Completed44 enrolled
NCT00595686 2012-05-17Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological MalignanciesEsanex Inc.Phase 1 Completed25 enrolled